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Abstract
Pneumococcal meningitis is associated with high morbidity and mortality rates. Brain damage caused by this disease is
characterized by apoptosis in the hippocampal dentate gyrus, a morphological correlate of learning deficits in experimental
paradigms. The mood stabilizer lithium has previously been found to attenuate brain damage in ischemic and inflammatory
diseases of the brain. An infant rat model of pneumococcal meningitis was used to investigate the neuroprotective and
neuroregenerative potential of lithium. To assess an effect on the acute disease, LiCl was administered starting five days
prior to intracisternal infection with live Streptococcus pneumoniae. Clinical parameters were recorded, cerebrospinal fluid
(CSF) was sampled, and the animals were sacrificed 42 hours after infection to harvest the brain and serum. Cryosections of
the brains were stained for Nissl substance to quantify brain injury. Hippocampal gene expression of Bcl-2, Bax, p53, and
BDNF was analyzed. Lithium concentrations were measured in serum and CSF. The effect of chronic lithium treatment on
spatial memory function and cell survival in the dentate gyrus was evaluated in a Morris water maze and by quantification
of BrdU incorporation after LiCl treatment during 3 weeks following infection. In the hippocampus, LiCl significantly reduced
apoptosis and gene expression of Bax and p53 while it increased expression of Bcl-2. IL-10, MCP-1, and TNF were
significantly increased in animals treated with LiCl compared to NaCl. Chronic LiCl treatment improved spatial memory in
infected animals. The mood stabilizer lithium may thus be a therapeutic alternative to attenuate neurofunctional deficits as
a result of pneumococcal meningitis.
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Introduction
Pneumococcal meningitis (PM) causes high mortality and
morbidity and leads to persisting sequelae in up to 50% of
affected children, including deficits in academic, executive and
intellectual performance, which persist into adulthood [1–4].
Injury to the brain occurs in 3 specific forms characterized by
sensorineural hearing loss due to damage to the inner ear,
ischemic necrosis of the cortex and apoptosis in the dentate gyrus
(DG) of the hippocampus. The latter from of brain damage is
found in patients and experimental models and is regarded as the
histomorphologic correlate of learning deficits [5–7]. Neuronal
apoptosis occurs by caspase-dependent and caspase-independent
pathways and is most likely caused by multiple factors including an
overshooting inflammatory reaction and bacterial toxins [8,9].
Lithium is the mainstay treatment of bipolar disorders [10].
Several studies have suggested that lithium can be used in the
treatment of acute brain injuries (e.g. ischemia) and chronic
neurodegenerative diseases (e.g. Alzheimer’s disease, amyotrophic
lateral sclerosis [ALS], Parkinson’s disease [11–14]). Lithium is
water-soluble, does not bind to plasma proteins and rapidly
reaches the brain where it has been described to accumulate in the
cells [15]. Clinically, it is administrated in the form of lithium salts,
e.g. LiCl and excreted without metabolization by the kidneys
where around 80% are reabsorbed in the proximal tube [10].
Lithium serum concentrations have to be closely monitored to
prevent toxic effects which are observed above 1.5 mmol/l while
neurological symptoms are associated with serum levels .
2 mmol/l [16,17]. Recommendations aim at 0.6–1.0 mmol/l
lithium serum concentrations while concentrations above
0.4 mmol/l have been accepted to be effective in chronic
treatment of bipolar disorder and are used in studies evaluating
lithium in other neurodegenerative paradigms, e.g. ALS [12,17–
19]. The exact mechanisms of lithium action remain to be
elucidated, but effects on neurotransmitters (e.g. glutamate,
dopamine, GABA), second messenger signaling systems (glycogen
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synthase kinase 3 [GSK-3], inositol), and B-cell lymphoma
protein-2 (Bcl-2) have been described [10]. The protein kinase
GSK-3b plays a critical role in the central nervous system, is
expressed in neurons during remodeling, regulating multiple
processes of neurons, including cytoskeletal development to
establish polarity [20,21]. GSK-3b is rapidly and reversibly
inhibited by lithium through multiple pathways with an
IC50,2 mmol/l, while the mood stabilizing effects are apparent
after chronic administration aimed at concentrations of
,1 mmol/l and may involve different mechanisms [22–24].
GSK-3 promotes the mitochondria-mediated intrinsic apoptotic
signaling pathway and inhibits the extrinsic apoptotic signaling
pathway [22]. Both pathways culminate in caspase activation and
eventually apoptosis.
Lithium up-regulates anti-apoptotic molecules such as Bcl-2,
brain-derived neurotrophic factor (BDNF) and b-catenin while
down-regulating pro-apoptotic molecules like Bcl-2-associated X
protein (Bax), tumor protein p53, and caspases [11,25]. Up-
regulation of Bcl-2 was observed in chronically treated rodents
with lithium plasma concentrations of ,0.3 mmol/l [20,26]. This
may be relevant for the treatment of bacterial meningitis, since
interventions influencing apoptotic processes have been beneficial
in experimental models [8]. Similarly in experimental PM, gene
expression of BDNF was enhanced and BDNF administration was
neuroprotective [27,28].
In addition to its neuroprotective properties, lithium is known to
enhance neurogenesis and to promote neuronal differentiation of
progenitor cells [11,26,29]. In vitro, lithium application and
down-regulation of GSK-3b resulted in increased proliferation of
adult hippocampal progenitors [30]. The hippocampus is a crucial
structure for the formation of episodic and spatial memory and is
implicated in emotional behavior and spatial memory [31,32].
The DG is a stem cell niche with continuous formation of new
neurons throughout life and therefore potentially well equipped for
repair [33]. PM specifically injures these stem cells and their
progenitors and thus permanently impedes endogenous brain
repair mechanisms, a fact that may explain the persisting
neurofunctional deficits in survivors of PM [34]. Nevertheless,
this brain region would, by its neurogenic potential, be well
equipped for repair and increased neuronal proliferation is indeed
observed shortly after bacterial meningitis, but it is neither
sufficient nor sustainable [28,35,36]. The Morris water maze
evaluates predominantly spatial memory and hippocampal apo-
ptosis is associated with decreased learning performance in this
task [37–39].
We therefore hypothesized that lithium prevents hippocampal
apoptosis in acute experimental PM by down-regulating expres-
sion of pro-apoptotic genes, while up-regulating anti-apoptotic
genes. Further into the investigation of its effects in PM, LiCl was
applied in a clinically relevant setting, i.e. after infection, to
evaluate its impact on the neurofunctional outcome. We
hypothesized that lithium supports neuronal regeneration by
increasing proliferation and survival of neuronal stem/progenitor
cells in the damaged hippocampus eventually improving neuro-
functional outcome. Thus, we evaluated the survival of new-born
cells in the DG during three weeks following PM while the animals
were treated with LiCl. Based on its neuroprotective and
neuroregenerative properties, this is the first study evaluating
lithium as a potential therapeutic strategy in the context of
bacterial meningitis.
Materials and Methods
Infecting organism
A clinical isolate of Streptococcus pneumoniae (serotype 3), was
cultured overnight in brain heart infusion medium, diluted in fresh
medium, and grown for 5 h to logarithmic phase as reported
earlier [40]. Bacteria were pelleted by centrifugation for 10 min at
196006g, and re-suspended in sterile, pyrogen-free saline to the
desired optical density. The accuracy of the inoculum size was
routinely confirmed by quantitative cultures on sheep blood agar
plates.
Infant rat model of PM
All animal studies were approved by the Animal Care and
Experimentation Committee of the Canton of Bern, Switzerland
(license BE 100/11) and followed the Swiss national guidelines for
the performance of animal experiments. A well-established infant
rat model of PM was used as previously described [40,41]. Litters
of 12 nursing Wistar rats with their dam were obtained from
Charles River (Sulzfeld, Germany) and acclimatized for 6 days
prior to infection on postnatal day 11 (P11) by intracisternal (i.c.)
injection of 10 ml 0.85% NaCl containing log10 5.9965.78 cfu/ml
live S. pneumoniae (PM+). Non-infected control animals received
i.c. injections of 10 ml sterile 0.85% NaCl (PM2). PM was
confirmed by quantitative analysis of bacterial titers in CSF
samples, when animals developed symptomatic disease at 18 h
post infection (hpi). To assess disease severity, the rats were
weighed and examined clinically at 0, 18, 26 hpi, and before
sacrificing at 42 hpi. The severity of the disease was scored as
follows: 1 = coma; 2 = does not stand upright; 3 = stands upright
within 30 seconds; 4 =minimal ambulatory activity, stands upright
in less than 5 seconds; and 5= normal. For ethical reasons,
animals reaching a score of 2 or below were sacrificed with an
overdose of pentobarbital (Esconarkon, Streuli, Uznach, Switzer-
land, 150 mg kg21 d21, i.p.); spontaneous mortality was docu-
mented. Antibiotic therapy with ceftriaxone (Rocephine,
26100 mg kg21 d21 i.p., Roche Pharma, Basel, Switzerland)
was started at 18 hpi. Animals were provided with water and food
ad libitum at natural light cycles.
Figure 1. At the time of sacrifice, lithium concentrations in
serum and cerebrospinal fluid (CSF) of infected animals show a
significant correlation (r =0.91; p,0.0001; n=15).
doi:10.1371/journal.pone.0113607.g001
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Pre-treatment with LiCl in acute PM
Based on previous reports, increasing concentrations of lithium
(2, 20, 27, 57, and 63 mg kg21 d21 LiCl, LiDCO, Interdelta AG,
Givisiez, Switzerland) were evaluated [15,42–44]. The animals
were randomized to receive either subcutaneous (s.c.) injections of
LiCl (n = 64) in a volume of 10 ml/g body weight (b.w.), or an
equivalent volume of NaCl 0.85% (n= 53) five days prior to
infection (P6) as described above. Punctures of the cisterna magna
were performed to obtain CSF samples using a 30 G needle at 18
hpi and 42 hpi. CSF bacterial titers were determined on blood
agar plates or CSF was centrifuged (1690006g at 4uC for 10 min)
and supernatants frozen at 280uC until further use. Animals were
sacrificed with an overdose of pentobarbital at 42 hpi. Blood
samples were obtained by puncture of the right atrium. After
coagulation, serum was isolated and stored at 280uC until further
use. For histological analysis the animals were perfused with 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) prior
to remove their brains and post-fix them in PFA. For gene
expression analysis the animals were perfused with ice cold PBS,
the brains were dissected, the left hippocampi were isolated and
stored in RNAlater solution (Life technologies, Carlsbad, CA,
USA) for 1 day at 4uC and thereafter at 280uC until RNA
isolation, while the right hemispheres were post-fixed in PFA for
24 h and used for histology.
Lithium measurements by capillary electrophoresis
Serum lithium concentrations were measured approximately
12 h after the last dose [16,45]. Lithium concentrations were
measured in serum and CSF samples using capillary electropho-
resis. The assay employed was similar to that of Pascali et al. [46].
Briefly, 25 ml serum or CSF was diluted 10-fold with water and
barium served as internal standard. The running buffer contained
imidazole (10 mmol/l), 2-hydroxybutyric acid (15 mmol/l), 18-
crown-6-ether (7.5 mmol/l), and sodium hydroxide (15 mmol/l)
and was adjusted to pH 4.5 with a few drops of 1 M acetic acid.
Samples were analysed on a P/ACE MDQ system (Beckman
Coulter, Fullerton, California, USA) using a 75 mm ID fused-silica
capillary of 60 cm total length at 20uC and an applied voltage of
16 kV. Samples were pressure injected during 5 s at 0.5 psi.
Quantitation was based on a 5-level internal calibration (between
0.24 and 1.89 mmol/l lithium) using corrected peak areas detected
at 214 nm and the 32 Karat software (Version 7.0, Beckman
Coulter). The limits of quantitation and detection for lithium were
0.10 mmol/l and 0.03 mmol/l, respectively.
Histomorphometrical analysis
Brain damage was quantified in animals sacrificed at 42 hpi as
previously described [41,47]. The brains were fixed in PFA and
cryopreserved in 18% sucrose in PBS at 4uC overnight. In animals
used for RNA isolation, only the right hemispheres were used for
histomorphometrical analysis. Coronal brain cryosections (45 mm-
Table 1. Cyto-/chemokine levels were measured in cerebrospinal fluid samples of infant rats 18 h after infection.
NaCl (n =20)a Lithium (n=17)a,b P value
TNF [pg/ml]c 8776544 (971, 95, 1780) 190561166 (1723, 559, 5100) 0.0012**
IL-6 [ng/ml]c 1946100 (211, 34, 354) 193682.2 (179, 72, 414) 0.8828
IL-1b [ng/ml]c 2.061.4 (1.7, 0.09, 5.5) 1.560.8 (1.3, 0.3, 3.7) 0.2793
MIP-1a [ng/ml] 6.164.0 (6.2, 0.7, 16.5) 6.864.4 (6.0, 1.5, 16.6) 0.6020
MCP-1 [ng/ml] 136651 (144, 55, 226) 180651 (171, 83, 287) 0.0155*
IL-10 [pg/ml] 9526541 (928, 191, 2114) 14866730 (1279, 306, 2707) 0.0154*
IFN-c [ng/ml]c 20.2620.1 (15.8, 0.8, 75.7) 11.567.7 (12.7, 0.6, 28.3) 0.2666
avalues are mean 6 standard deviation (median, min., max.);
blithium serum conc. 0.4 mmol/l – 1.5 mmol/l;
cnon-parametric distribution; *, p,0.05; **, p,0.01; TNF, tumor necrosis factor; IL, interleuki n; MCP-1, monocyte chemoattractant protein 1; MIP-1a, macrophage
inflammatory protein 1 a; IFN-c, interferon gamma.
doi:10.1371/journal.pone.0113607.t001
Figure 2. Cyto-/chemokine concentrations in cerebrospinal fluid samples of rats with pneumococcal meningitis and treated with
NaCl or LiCl were measured 18 h after infection. All cyto-/chemokines measured were elevated in infected animals receiving LiCl compared to
their littermates receiving NaCl. For TNF (A), IL-10 (B), and MCP-1 (C) this difference reached statistical significance. (TNF, tumor necrosis factor; IL,
interleukin; MCP-1, monocyte chemoattractant protein 1; boxes extend from the 25th to 75th percentiles and include median; +, mean; whiskers,
minimum to maximum value; *, p,0.05; **, p,0. 01).
doi:10.1371/journal.pone.0113607.g002
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thick) obtained by systematic uniform random sampling were
stained for Nissl substance with cresyl violet. Cortical damage was
defined as areas of decreased neuronal density or frank cortical
necrosis by simultaneous bright-field microscopy and scanned
Figure 3. Apoptosis in the hippocampal dentate gyrus of survivors of bacterial meningitis was quantified in cryosections 42 h after
infection. (A) LiCl treatment reduced apoptosis significantly compared to littermates treated with NaCl. (B) Hippocampal apoptosis was significantly
attenuated in animals with lithium serum concentrations $0.4 mmol/l compared to NaCl treated littermates. (C) A dose-dependent effect of LiCl on
hippocampal apoptosis is observed (r =20.43, p,0.001, n = 55). (C) Lithium serum concentration and apoptosis in infected rats treated with 2–
63 mg/kg LiCl correlate weakly (r =20.28, p = 0.04, n = 55). (Boxes extend from the 25th to 75th percentiles and include median; +, mean; whiskers,
minimum to maximum value; *, p,0.05).
doi:10.1371/journal.pone.0113607.g003
Figure 4. Cortical damage was quantified 42 h after induction of bacterial meningitis in cryosections. (A) LiCl treatment reduced
cortical injury without reaching statistical significance when compared to littermates treated with NaCl. (B) The effect was below statistical
significance when comparing animals with lithium serum concentrations $0.4 mmol/l to NaCl treated littermates. (Boxes extend from the 25th to
75th percentiles and include median; +, mean; whiskers, minimum to maximum value).
doi:10.1371/journal.pone.0113607.g004
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digitized images using the software ImageJ 1.45l (National
Institutes of Health, USA, http://imagej.nih.gov/ij). The volume
of cortical brain damage was expressed as a percentage of the total
cortical volume determined using the Cavalieri principle by
investigating 16 brain sections per animal as described in details
previously [48]. Histological features of apoptosis (condensed,
fragmented dark nuclei, apoptotic bodies) were counted in 4
different slices spanning the hippocampus of both hemispheres (in
brains used for gene expression only the right hemisphere) by a
person blinded to the experimental grouping. Apoptotic cells were
counted in three visual fields in each of the two blades of the DG
and a mean value per animal (totally 48 field, 24 fields for brains
used for RNA isolation) was calculated.
Quantitative analysis of cytokines in CSF
A panel of cyto- and chemokines known to be involved in the
pathophysiology of bacterial meningitis was selected to document
the inflammatory response in the present infant rat model of PM
[49]: tumor necrosis factor (TNF-a), interleukin-6 (IL-6), IL-1b,
IL-10, monocyte chemoattractant protein 1 (MCP-1), macrophage
inflammatory protein 1 a (MIP-1a), interferon gamma (IFN-c)
[50]. The concentration of these analytes was determined in the
CSF using microsphere-based multiplex assays (MILLIPLEX
MAP Kit, Rat Cytokine/Chemokine Magnetic Bead Panel, Cat.
#RECYTMAG-65K; Millipore Corporation, Billerica, MA). 5 ml
of CSF supernatant were diluted to a final volume of 25 ml using
the provided assay buffer. A minimum of 50 beads per analyte was
measured using a Bio-Plex 200 station (Bio-Rad Laboratories,
Hercules, CA). Calibration curves from recombinant standards
were calculated with Bio-Plex Manager software version 4.1.1
using a five-parameter logistic curve fitting. If the sample
concentration was below detection limit, the value of the detection
limit as provided by the manufacturer and multiplied by the
dilution factor used for statistical analysis, i.e. TNF-a 9.5 pg/mL,
IL-6 153.5 pg/mL, IL-1b 14 pg/mL, IL-10 13.5 pg/mL, MCP-1
45 pg/mL, MIP-1a 4.0 pg/mL, IFN-c 31 pg/mL.
RNA isolation
RNA isolation was performed as previously described [51]. In
brief, hippocampi were put into 1 ml QIAzol Lysis reagent
(Qiagen) and immediately homogenized by a rotor-stator homog-
enizer (TissueRuptor, Qiagen). RNA was isolated using the
RNeasy Lipid Tissue Mini Kit (Qiagen), following the manufac-
turers protocol. To remove contaminating DNA, 20 ml isolated
RNA was treated with DNase using the DNA-free Kit (Ambion,
Carlsbad, CA, USA). RNA quality and quantity were determined
on the Agilent 2100 Bioanalyzer platform (RNA 6000 Nano,
Agilent Technologies, Waldbronn, Germany) and validated on the
NanoDrop device (NanoDrop, Wilmington, USA). Only RNA
with sufficient quality (RIN.8) and purity (OD260/OD280 nm
absorption ratio .1.95) were further used. Absence of genomic
DNA and unspecific binding of primers was confirmed in qPCR
by not reaching the threshold after 40 cycles in samples without
reverse transcription.
Quantitative real-time polymerase chain reaction (qPCR)
Synthesis of cDNA was performed with the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA), utilizing 1.5 mg of RNA according to the manufactur-
er’s instructions. The cDNA samples were diluted 1:10 with
RNase-free water and stored at 220uC. QuantiFast Probe PCR
kit (Qiagen, composed of Hot Star Taq Plus DNA polymerase and
dNTP mix in PCR buffer) and TaqMan Gene Expression Assays
(Applied Biosystems) were used to perform quantitative real-time
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PCR (qPCR) in technical triplicates in 20 ml reaction volume on
the Quant Studio 7 Flex station (Applied Biosystems). Non-
template controls were used to confirm absence of contaminating
DNA. The following primers (Applied Biosystems) were used: bdnf
(BDNF, Rn02531967_s1), bcl2 (Bcl-2, Rn99999125_m1), tp53
(p53, Rn00755717_m1), and bax (Rn02532082_g1). Parameters
for baseline and threshold-cycle (Ct) settings were kept constant for
each gene. To calculate DCt of each investigated gene, the gene
rpl24 encoding the L24 ribosomal protein (Rn00821104_g1) was
used as normalizer [50,51]. DDCt values were calculated by
subtracting the DCt values obtained for LiCl treated animals from
the mean DCt value obtained for the controls (PM2/NaCl treated
animals). Relative fold increases were calculated using the formula
22DDCt [52].
Chronic lithium treatment after acute PM
84 animals were randomized for infection (PM+; n = 56;
inoculum log10 5.7265.49 cfu/ml) or mock-infection (PM2;
n = 28). Some animals were excluded because the infection was
not successful (n = 6) or the animals died between P13 and P35
(PM+/LiCl: n = 4; PM2/NaCl: n= 2). The remaining infected
animals (n = 46) received s.c. injections of 57 mg kg21 d21 LiCl
(LiDCO; n=15), 110 mg kg21 d21 LiCl (Lithium Chloride,
Molecular Biology Grade, Calbiochem; La Jolla, CA, USA;
n= 7) or an equal volume of NaCl 0.85% (n= 24). 25 animals died
due to the infection within 42 hpi (57 mg kg21 d21 LiCl: n = 7,
110 mg kg21 d21 LiCl: n = 6, NaCl: n = 12). In the mock-
infection group, 10 animals received 57 mg kg21 d21 LiCl
(LiDCO), 4 animals received 110 kg21 d21 LiCl (Calbiochem)
and 12 animals received an equal volume of NaCl 0.85%. The first
dose was given at 22 hpi, the last one 12 h before sacrificing on
P35. All animals were treated with ceftriaxone (26100 mg
kg21 d21 i.p.) for 5 days and received pulses of 5-Bromo-29-
deoxyuridine (BrdU, 50 mg kg21, B5002, Sigma-Aldrich, Buchs,
Switzerland) at 18, 42, and 66 hpi.
Neurofunctional outcome (Morris water maze)
Learning performance was evaluated between P31 and P35 in
the Morris water maze task after chronic lithium treatment as
previously described in all surviving animals [53,54]. Gross
vestibulomotor dysfunction was first tested by Rota Rod. Animals
had to stay on the rotating rod (8 rpm; Ugo Basile srl, Comerio,
Italy) for more than 30 seconds, otherwise they were excluded
from the water maze test (n = 2). Swimming patterns of the rats
were registered with the video tracking system EthoVision XT
(Version 8.5, Noldus Information Technology, Wageningen, The
Netherlands). The water surface was virtually divided into four
quadrants. An adjustable platform measuring 16613 cm was
placed in the center of the first quadrant 0.5 cm below the water
surface. Three entry zones in the other quadrants were marked
outside the pool. The animals were given 3 days to acclimatize in a
light cycle of 12 h light–12 h darkness in the water maze
Figure 5. Gene expression of proteins involved in apoptotic pathways was analyzed in hippocampi of 13 days old rats. In mock-
infected animals (PM2), gene expression of Bax, Bcl-2, and p53 was not significantly altered by LiCl treatment during 5 days. LiCl treatment
significantly reduced gene expression of pro-apoptotic proteins Bax and p53 42 h after induction of meningitis (PM+). Gene expression of the anti-
apoptotic Bcl-2 was increased in the LiCl group compared to NaCl. (Boxes extend from the 25th to 75th percentiles and include median; whiskers,
minimum to maximum value; bcl2, B-cell lymphoma protein-2; bax, Bcl-2-associated X protein; tp53: tumor protein p53; *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0113607.g005
Table 3. Three weeks after infection, the effect of chronic lithium treatment was evaluated in a water maze.
PM2/NaCl,
(n = 12)a
PM2/LiCl,
(n = 12)a
P
valueb
PM+/NaCl,
(n = 11)a
PM+/LiCl,
(n =8) a P valueb
Time to reach
platform [s]
8.3
(6.0, 13.5)
9.8
(5.7, 15.1)
0.7279 12.4
(7.7, 27.4)
11.8
(5.9, 23.8)
0.1558
Distance moved to
reach platform [cm]
211.0
(146.3, 434.9)
230.8
(128.1, 447.4)
0.8276 302.7
(196.2, 968.4)
294.6
(176.6, 793.3)
0.2530
In training trials, the treatment had no effect on time and distance to reach the platform on day 4.
avalues are median (25% percentile, 75% percentile);
bMann-Whitney test; PM, pneumococcal meningitis.
doi:10.1371/journal.pone.0113607.t003
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experimental room. The animals performed five training trials
(TT) per day, with the invisible platform in a fixed position
between P31 and P34. Before TT and on P35 one probe trial (PT)
without the platform was performed. Facing the tank wall, the rats
Figure 6. Learning capacity was assessed in the Morris water maze after 4 training days. In probe trials, the mean distance of the animals
to the previous location of the platform was calculated. LiCl led to a significantly improved learning capacity compared to NaCl on day 5 (2way
ANOVA). In post-hoc analysis, the effect of LiCl treatment was significant in infected animals (PM+) while it remained below statistical significance in
mock-infected animals (PM2). (Boxes extend from the 25th to 75th percentiles and include median; +, mean; whiskers, minimum to maximum value;
*p,0.05).
doi:10.1371/journal.pone.0113607.g006
Figure 7. Three weeks BrdU injections to animals with bacteriologically cleared meningitis, BrdU incorporating cells were counted
in the dentate gyrus of the hippocampus to quantify cell survival. (A, B) Representative image of a mock-infected animal receiving NaCl
shows sporadic presence of BrdU positive cells. (C, D) A mock-infected animal treated with LiCl for 3 weeks shows enhanced presence of BrdU
positive cells in the DG. (BrdU, Bromodeoxyuridine; DAPI, 49,6-diamidino-2-phenylindole).
doi:10.1371/journal.pone.0113607.g007
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were put into the water at one of the entry zones determined by
randomization. If an animal found the platform within 90 s, it was
allowed to stay on it for 15 s before put back to the cage. If the rat
did not find the platform within 90 s, it was guided there by hand
and was allowed to stay on it for 15 s. Between trials, the animals
rested for 45 min. During TT, total time and distance to reach the
platform and velocity were recorded. In PT the mean distance to
the center of the virtual platform, the time spent in the quadrant
that contained the platform, and the number of crossings through
the virtual platform was recorded in the first 30 s of each run. The
animals were sacrificed on P35 by an overdose of pentobarbital.
Blood samples were obtained by puncture of the right atrium and
the serum stored at 280uC until further use. The animals were
perfused with ice cold PBS. The brains were dissected and fixed in
methanol/acetic acid (95:5) at 4uC.
Evaluation of BrdU incorporation (immunohistology)
Hippocampal density of BrdU positive cells was quantified in all
survivors after receiving chronic lithium treatment for 3 weeks. To
exclude any influence of the training during water maze on BrdU
density, only animals successfully finishing this task were included.
After fixation in a solution of methanol and acetic acid the brains
were embedded in paraffin. 10 mm sections were prepared as
previously described [34,55]. Anti-BrdU sheep polyclonal anti-
body (1:1000; Abcam, Cambridge, UK) and the secondary goat
anti-sheep Cy3-conjugated antibody (1:1,000; Jackson ImmunoR-
esearch Laboratories, West Grove, PA, USA) were used and
counterstained with 49,6-Diamidin-29-phenylindol-dihydrochlorid
(DAPI). For cell density counting, digitized images, acquired using
a fluorescence microscope and a charge-coupled device camera,
were used (AxioImager.M1, Zeiss, Germany). Using ImageJ
software (NIH), the outlines of the dentate gyrus were determined
on the DAPI-stained image and superimposed on the BrdU image.
After calibration, the surface areas were determined and cell
proliferation determined as the number of BrdU positive cells/
mm2 [34].
Statistical analysis
Statistical analyses were performed by using GraphPad Prism
software (Prism 6 for Windows, GraphPad Software Inc., San
Diego, CA). If not stated otherwise, results are presented as mean
values 6 standard deviation. The D’Agostino & Pearson omnibus
normality test was used to discriminate between parametric and
non-parametric values. To compare data between two groups an
unpaired Student’s t test was used for parametric data. To
compare four groups, two-way analysis of variance (2way
ANOVA) was used together with Sidak’s multiple comparisons
test for post-hoc analysis. Non-parametric groups were pairwise
analyzed with a Mann-Whitney test. Mortality rates were
calculated using log rank (Mantel-Cox) test for significance based
on all successfully infected animals and numbers of animals
sacrificed due to ethical reasons (clinical score#2) or dying
spontaneously. For post-hoc power analysis an online tool was
used (http://clincalc.com/Stats/Power.aspx). A chi-square test
was used to compare animals with cortical injury to littermates
without damage (defined as less than 0.5% affected cortex). A two-
tailed P value of ,0.05 was considered statistically significant.
Results
Pre-treatment with lithium in acute PM
Clinical and inflammatory parameters. Lithium concen-
trations were measured in serum and CSF at 42 hpi and clinical
and inflammatory parameters were determined to evaluate
severity of the disease. Application of 2 mg kg21 LiCl was
insufficient to reach measurable serum concentrations of lithium.
Therefore, animals with this treatment regimen (n = 36) were
excluded from further analyses (except for correlations of
hippocampal apoptosis with LiCl dosage and lithium serum
concentrations). 53 of 62 rats in the NaCl group and of 64 of 67
rats in the lithium group were successfully infected, which was
confirmed by bacterial growth in the CSF at 18 hpi and
symptomatic disease, i.e. clinical score ,5. Therapeutically
effective serum concentrations were defined as 0.4–1.5 mmol/l
Figure 8. BrdU was applied on P12–14, starting on the first day after infection. The animals were sacrificed on P35 and coronary brain
sections were stained for BrdU. In mock-infected animals (PM2), the density of BrdU positive cells in the dentate gyrus was significantly higher after
LiCl therapy compared to vehicle, while survival of newborn cells was not altered in infected littermates (PM+). (BrdU, Bromodeoxyuridine; boxes
extend from the 25th to 75th percentiles and include median; +, mean; whiskers, minimum to maximum value; *p,0.05).
doi:10.1371/journal.pone.0113607.g008
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[17,18] and were achieved with a dosage between 20 and 63 mg
kg21 d21 LiCl. The mean 6 SD lithium serum concentration
obtained with this treatment regimen was 0.4760.38 mmol/l
(n = 38; range 0.0–1.5 mmol/l) and correlated with the dosage of
LiCl applied (r = 0.79; p,0.0001). At the time of sacrifice, in
infected animals lithium concentrations in CSF and those assessed
in serum correlated (r = 0.91; p,0.0001, n= 15; Fig. 1) and
lithium levels in CSF were higher compared to those of serum
(slope 0.6460.06; Fig. 1).
The weight gain during pre-treatment was reduced in animals
receiving lithium compared to littermates receiving saline (NaCl:
12.061.5 g, n= 53; LiCl: 10.661.5 g, n= 64; p,0.0001) and
correlated inversely with LiCl dosage (r =20.40, p = 0.001,
n = 64). Consequently, at the time of infection animals receiving
lithium weighed less than their littermates (NaCl: 26.262.5 g,
n = 53; LiCl: 24.962.7 g, n= 64; p,0.01). Weight changes
between infection and 42 hpi did not vary significantly between
treatment groups (NaCl: 20.13160.052%, n= 34; LiCl: 2
0.12660.048%, n= 38; p= 0.50).
At 18 hpi, bacterial titers in CSF were equal between treatment
groups (NaCl: log10 7.8568.08 CFU/ml; LiCl: log10
7.9067.96 CFU/ml). Survival rates during PM were not signif-
icantly changed by lithium pre-treatment (NaCl: 64.1%, n= 53;
LiCl: 60.9%, n= 64; p = 0.73).
Cyto-/chemokines were measured in the CSF at 18 hpi
(Table 1, Fig. 2). IL-10, MCP-1, and TNF were significantly
increased in animals treated with LiCl (n = 17) compared to
littermates receiving NaCl (n = 20). Several cyto-/chemokines
correlated with serum lithium concentrations measured at 18 hpi:
MIP-1a (p = 0.02, r = 0.65), IL-1b (p,0.01, r = 0.75), IL-10 (p,
0.005, r = 0.76).
Brain injury. Histomorphometric analysis of hippocampal
apoptosis and cortical necrosis was performed on the brains from
animals sacrificed at 42 hpi to evaluate neuroprotective effects of
lithium. In mock-infected animals (PM2/NaCl and PM2/LiCl)
apoptotic cells in the DG were present only sporadically and no
injury to the cortex was detected as opposed to infected animals
(PM+/NaCl and PM+/LiCl).
A significant reduction of hippocampal apoptosis was observed
in animals treated with a dosage of 20–63 mg kg21 d21 LiCl in
comparison to their littermates receiving NaCl (NaCl: 10.468.7
apoptotic cells per visual field [c/f], median 6.1 c/f, n = 34; LiCl:
7.9610.3 c/f, median 3.5 c/f, n = 38; p = 0.03, Fig. 3A). When
lithium serum concentrations exceeded 0.4 mmol/l, animals
displayed significantly reduced levels of hippocampal apoptosis
compared to littermates receiving NaCl (6.468.5 c/f, median 3.4
c/f, n = 19; p = 0.03; Fig. 3B). In animals with a lithium serum
concentration ,0.4 mmol/l this effect did not reach statistical
significance (9.5611.9 c/f, median 4.6 c/f, n = 19; p = 0.48). A
dose-dependent effect of lithium could be demonstrated with a
significant inverse correlation between the amount of hippocampal
apoptosis and increasing LiCl dosages (r =20.43, p,0.001,
n = 55; Fig. 3C). The inverse correlation between measured
lithium serum concentrations and the number of apoptotic cells
was weaker (r =20.28, p= 0.04, n = 55; Fig. 3D).
Cortical injury was reduced by LiCl treatment without reaching
statistical significance when compared to the NaCl group (NaCl:
8.4612.2%, median 0.9%; LiCl: 3.165.5%, median 0.7%;
p= 0.16; statistical post-hoc power: 65.1%; Fig. 4A). Lithium
serum concentrations higher than 0.4 mmol/l did not lead to
significantly less cortical injury (lithium serum conc.,0.4 mmol/l:
2.164.4%, median 0.5%; lithium serum conc. $0.4 mmol/l:
4.166.3%, median 0.9%; p= 0.80; Fig. 4B). 19 of 40 (47.5%)
infected animals treated with LiCl showed cortical injury as
compared to 20 of 34 (58.8%) in NaCl treated littermates (Chi
square test: p = 0.81).
Gene expression analysis. To investigate whether the
observed prevention of hippocampal apoptosis could be explained
by a direct effect of lithium on apoptotic pathways, expression of
bcl-2, bax, and tp53 genes was analyzed in the hippocampus of
mock-infected and infected animals with and without LiCl
treatment at 42 hpi. The rpl24 gene served as normalizer as
described earlier [50,51]. In mock-infected animals treated with
LiCl, expression of the analyzed genes did not change significantly
compared to animals. In infected animals expression of bax and
p53 genes was significantly up-regulated (p= 0.005, and p,0.05,
respectively; 2way ANOVA) compared to mock-infected animals
(Fig. 5; Table 2). In infected animals treated with LiCl, bax and
p53 gene expression was down-regulated (p= 0.04 and p=0.01,
respectively), whereas expression of bcl-2 gene was up-regulated
(p = 0.02) compared to NaCl treated littermates. In infected
animals treated with LiCl, bdnf showed decreased expression
without reaching statistical significance.
Chronic lithium treatment after acute PM
LiCl was applied in a clinically relevant setting, after the animals
developed symptomatic meningitis on the first day after infection.
The LiCl dosage applied in the pre-treatment study was used for
chronic treatment (57 mg kg21 d21). With this regimen, lithium
concentrations measured after 3 weeks of daily LiCl applications at
P35 were lower than concentrations measured after 5 days pre-
treatment at P13. Therefore, the dose was raised to 110 mg
kg21 d21. However, serum levels were not significantly increased
under the new treatment schedule at P35. Overall, mean lithium
serum concentration was 0.0960.08 mmol/l (range 0.00–
0.21 mmol/l; n = 13) in mock-infected animals and
0.0660.08 mmol/l (range 0.00–0.22 mmol/l; n = 8) in infected
animals measured at P35.
Neurofunctional outcome (Morris water maze). To
evaluate the effect of lithium treatment in a clinical setting,
neurofunctional outcome was measured in the Morris water maze
test 3 weeks after infection in all survivors. Mock-infected and
infected animals receiving LiCl during these 3 weeks were
compared to their littermates receiving NaCl (PM2/NaCl:
n = 12; PM2/LiCl, n = 14; PM+/NaCl, n= 12; PM+/LiCl,
n = 9). Gross vestibulomotor dysfunction was excluded by ability
to stay on a rotating rod in all survivors, except in two animals of
the PM2/NaCl group which were excluded from the study.
Learning behaviors, evidenced by decreased distance and time to
reach the platform during the training sessions were observed in all
four groups over a four-day period.
Compared to uninfected animals, NaCl treated, infected
animals swum a statistically significant longer distance (p,0.005,
Mann-Whitney test; Fig. 6) and used statistically significant more
time to reach the platform (p,0.01). In contrast, LiCl treated,
infected animals did not perform significantly different in this
learning assessment than mock-infected ones (distance: p = 0.08;
time: p = 0.46). The direct comparison of learning performance
between NaCl and LiCl treatment did not reach statistical
significance (Table 3).
During probe trials, the platform was removed. Mean distance
to the center of the previous location of the platform, number of
platform crossings and time spent in the platform’s quadrant were
measured. LiCl treatment significantly improved learning perfor-
mance measured by these three parameters at the end of the
learning process, i.e. on day 5 (Table 4). Differences between the
treatment groups did not reach statistical significance on days 1 to
4 (data not shown). The effect of lithium treatment was stronger
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than the effect of infection in the variations between groups
reaching statistical significance in the 2way ANOVA on day 5
(Table 4).
Survival of new-born cells quantified by BrdU
incorporation. We hypothesized that chronic lithium treat-
ment after acute PM improves neurofunctional outcome primarily
by enhancing proliferation and survival of immature neuronal
stem/progenitor cells in the DG [26,56,57]. To quantify survival
of DG cells that proliferated during and shortly after hippocampal
injury due to PM, rats received BrdU pulses 18, 42, and 66 h after
infection. The density of BrdU positive cells in the DG was
quantified after chronic LiCl treatment of three weeks (Fig. 7).
The effect of infection (p= 0.06, 2way ANOVA) and treatment
(p = 0.08) remained below statistical significance (interaction:
p = 0.22). Post-hoc analysis showed that in mock-infected animals,
LiCl treatment significantly increased the survival of BrdU
incorporating cells in the DG compared to NaCl application
(PM2/NaCl 424.9673.3, n = 12; PM2/LiCl: 515.16113.3,
n = 14; p,0.05, Fig. 8). In infected animals, LiCl had no influence
on the survival of new-born cells in the DG (PM+/NaCl:
395.5686.3, n= 10; PM+/LiCl 419.36106.4, n = 9; p= 0.93).
Discussion
To evaluate the effects of lithium treatment it was necessary to
find a valid treatment regimen. In the infant rat model of PM,
57 mmol/l LiCl was most effective to reach desired lithium serum
and CSF concentrations during pre-treatment, eventually pre-
venting hippocampal brain damage. However, a slightly reduced
weight gain in LiCl treated animals was observed during pre-
treatment, which could be explained by polyuria, a known adverse
effect of lithium [10,58]. The higher lithium levels found in CSF
compared to serum 42 h after infection might be explained by an
opened blood-brain barrier during neuroinflammation compared
to earlier studies performed in healthy animals [15,59].
Survival rates during acute PM were similar in animals
receiving lithium and littermates treated with NaCl. Clinical
disease severity and mortality are mainly influenced by systemic
manifestations of infection, e.g. sepsis, while the direct influence of
brain injury on these parameters is weak [60]. The effect of lithium
on inflammation is debated and its influence on mortality during
acute PM was expected to be weak [61]. In the infant rat model of
PM, most animals die within a time window of 20 and 27 hpi,
which was also the case in the present study [41]. Therefore, the
effect of chronic lithium treatment (initiated at 22 hpi) on mortality
rates was expected to be small. Mortality rates can vary
considerably in the animal model (inter-litter variability), but they
remained within expectation in the present study. After bacteri-
ologically cleared PM, the mortality rate was slightly higher in
animals chronically treated with LiCl compared to NaCl treated
littermates. We cannot rule out that temporary high lithium CNS
concentrations contributed to the death of these animals.
Lithium influences apoptotic pathways and prevents
hippocampal brain damage
Apoptotic injury in the DG of the hippocampus is a
neuropathologic hallmark of PM and starts to appear around 18
to 24 h after intracisternal infection in experimental models. It is
the result of a multifactorial process which includes an excessive
immune reaction to invading pneumococci and bacterial products
released in the CSF, while usually no direct contact of the bacteria
or infiltrating leukocytes with the DG is observed [7,8]. Different
approaches to reduce brain injury in PM by modulation of the
apoptotic machinery have been described earlier, but this is the
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first study investigating the mood stabilizer lithium in a paradigm
of acute neuroinfection [8]. Neuroprotective effects of lithium were
described in in vitro experiments, where the up-regulation of anti-
apoptotic Bcl-2 and down-regulation of pro-apoptotic p53 and
Bax were observed [11,62]. In mice, an increase of Bcl-2 in the
hippocampus was determined after 3–4 weeks of treatment with
Li, together with an increase in the number of dividing cells in the
DG [26]. Neuronal apoptosis due to hippocampal irradiation was
reduced in adult mice pre-treated for 7 days with lithium [63]. We
therefore hypothesized that lithium prevents apoptotic brain injury
in experimental PM by modulating expression of genes involved in
apoptotic pathways.
In the present study, pre-treatment for 5 days with LiCl
successfully reduced apoptosis in the hippocampal DG in an infant
rat model of PM. In this paradigm, LiCl had an anti-apoptotic
effect by decreasing gene expression of bax and tp53 while
increasing expression of bcl-2 in the hippocampus.
In the subset of animals randomly chosen for gene expression
analysis, the protective effect on LiCl on hippocampal apoptosis
was less pronounced than that of the overall study-population. The
effect on gene expression may therefore be more pronounced in
the total population of animals treated with lithium, in which the
prevention of apoptosis was more important.
The effect of LiCl treatment on gene expression in mock-
infected animals was only marginal. In the present study, CSF
levels of lithium were measured in infected animals, characterized
by an increased permeability of the blood brain barrier. It is
therefore conceivable that in non-infected animals the lack of an
effect of lithium on gene expression may be due to lower central
nervous system lithium levels compared to those of infected
animals. Alternatively, the dysregulated gene expression caused by
neuroinfection might have been down-modulated by the effect of
lithium.
Independently of LiCl treatment, the infection did not
significantly alter gene expression of BDNF at 42 hpi. During
bacterial meningitis, elevated levels of BDNF in serum and CSF
have been reported [28,64]. Different in vitro and in vivo models
showed increased BDNF expression after chronic treatment with
lithium, i.e. 14 days and longer [11,65,66]. Furthermore, increased
RNA and protein levels of BDNF were described in a mouse
model of PM only 4 days, but not 30 h after infection [28]. This is
in agreement with a microarray analysis performed in infant rats
with PM, showing that neuroregenerative processes are initiated 3
days after infection [55]. Therefore, we cannot exclude that the
infection regulates BDNF expression at later time points than the
one we tested in the present study.
Lithium increases cyto-/chemokines in CSF while it has
little effect on cortical injury
In PM, the mechanisms leading to cortical damage are
multifactorial and mostly related to inflammation and/or oxida-
tive damage and bacterial products [8,41]. In a model of cerebral
ischemia, reduction of infarct size and improved neurological
outcome after pre-treatment for 16 days with lithium has been
described [67]. In the present study, injury to the cortex was only
modestly reduced in lithium treated animals. Whether reduced
inflammation observed in some other experimental settings is a
primary effect of lithium application or results from less injury is
unknown [63]. Lithium has been described to act both, pro- and
anti-inflammatory and it is known to induce leukocytosis [61]. In
the present study, significant up-regulation of TNF, IL-10, and
MCP-1 during acute PM was observed in lithium-treated animals,
indicating a higher degree of inflammation while IL-1b and IFN-c
were down-regulated without reaching statistical significance.
Other reports described increasing IL-10 and decreasing TNF
concentrations after lithium treatment [61]. However, the effect of
lithium on these and other cytokines varied under different
conditions [61]. For example, one study reported increased TNF
secretion by neutrophils after lithium treatment during an acute
inflammatory reaction. In this study, mRNA levels of TNF were
not altered, indicating a post-transcriptional regulation [68].
TNF is an early response cytokine triggering an intense immune
response and has been targeted in meningitis models as a
therapeutic approach [41]. Though, inhibition of TNF activity
may be a double-edged sword and interventions aimed at specific
immunological mechanisms need to be well balanced [8]. Lithium
may increase inflammation locally, evidenced in the present study
by raised cyto-/chemokines in CSF samples, while having specific
anti-apoptotic properties and preventing hippocampal damage,
but not cortical necrosis.
In summary, LiCl was able to reduce apoptosis in the
hippocampus by favorably modulating the expression of genes
involved in the apoptotic machinery. In contrast, LiCl treatment
had no impact on weight loss or clinical score. Furthermore,
inflammation was not attenuated by LiCl administration and no
significant effect on cortical damage could be observed. These
proof-of-concept experiments were the basis to investigate the
effects of lithium in an adjuvant setting with a clinically relevant
treatment regimen.
Chronic lithium treatment after PM improves spatial
memory
The dosage used for pre-treatment (57 mg kg21 d21) was
applied in the study evaluating chronic lithium treatment starting
at 22 hpi, and resulted in serum levels of max. 0.22 mmol/l at
P35. An increase to 110 mg kg21 d21 did not increase serum
concentrations at P35, although lithium serum concentrations of
1.97 mmol/l and 2.64 mmol/l were measured in two infected
animals euthanized on P16. An effect of LiCl therapy, at the
measured serum concentrations, may be due to the higher lithium
serum levels that are reached at a younger age since serum
concentrations primarily depend on renal function which is lower
in infant rats. This is due to the fact that lithium is not metabolized
or bound to any proteins and urinary concentrating ability is fully
developed at around 6 weeks of age [45,69,70]. Alterations of
renal clearance, volume of distribution or other adaptations in the
infant rat may be responsible for the different lithium serum
concentrations measured at a different age.
In the present study in rats that survived PM, lithium led to
significantly improved learning performance during probe trials
compared to NaCl. The time and distance to reach the platform
during training trials decreased in all groups, without reaching
statistical significance when comparing animals with LiCl therapy
to their littermates receiving NaCl. In earlier studies, chronic
lithium treatment improved spatial memory assessed in a water
maze during different conditions, e.g. traumatic brain injury [71].
A correlation between hippocampal neurogenesis and learning has
been described earlier [72,73]. Lithium has been shown to
increase neurogenesis, e.g. evidenced by enhanced BrdU labelling
of cells in the DG and double-labelling with NeuN [19,26,56].
Also, an effect on long-term potentiation has been observed earlier
[57]. Immature neurons appear to become involved in spatial
memory at 15–20 days of age in rats [33]. Most immature cells die
within the first 2 weeks after proliferation, while training during
days 6–10 following BrdU injection enhanced survival [33]. PM
increases the proliferation of neuronal progenitor cells in the first
week after infection with a peak around 2 days post-infection and
thereafter declines to basal levels [36,55]. However, this increase
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in proliferation does not prevent learning deficits. In the present
study, this issue was addressed by daily applications of lithium over
3 weeks, starting on the first day after infection.
The effect of chronic lithium treatment on the survival of cells
born in the dentate gyrus 1 to 3 days after infection was evaluated
3 weeks later. While LiCl increased cell survival in mock-infected
animals, lithium therapy was not sufficient to prolong survival of
new-born cells in infected animals. Thus, the observations made
during neurofunctional assessment cannot be explained solely by
lithium-induced survival of new cells in the DG (neurogenesis).
Lithium’s ability to mobilize stem cells may contribute to the
observed beneficial outcome [74,75]. Furthermore, GSK-3 has a
critical function in regulating axon genesis and elongation and
inhibition by lithium stimulated axon formation and elongation of
mature neurons in vitro and in an in vivo model of spinal cord
injury [21]. Enhanced functional integration of surviving neurons
might be an alternative to explain the observed difference in the
water maze. Indeed, a recent study showed improved functional
recovery by lithium after intracerebral hemorrhage in rats without
affecting BrdU incorporation and doublecortin staining in the DG
[76]. We also cannot rule out that only the first doses of LiCl
applied during the very first days after infection may have acted
neuroprotective rather than neuroregenerative, explaining the
preserved learning capacity 3 weeks later. However, since steady
state levels of lithium are only reached after 1 week, i.e. later than
the development of brain damage, a neuroprotective effect of
lithium by chronic administration beginning at the onset of the
symptomatic disease is unlikely [10].
One of the main difficulties for lithium treatment is the narrow
therapeutic range of serum and CSF concentrations, while steady
concentrations are reached only after one week [10]. Furthermore,
the mechanistic functions of lithium at different concentrations are
widely unknown and lithium concentrations varied in animals with
a different age. We have addressed this issue by measuring CSF
concentrations at the time of sacrificing, however a continuous
observation of serum and CSF concentrations would be desirable.
Within the current study design it was not possible to explain the
beneficial effect of lithium on spatial memory.
Conclusion
Herein, lithium has shown a neuroprotective effect on
hippocampal brain damage when administered in the acute
disease. When given for a prolonged period after the disease,
lithium led to improved spatial memory. Thus the mood stabilizer
Lithium may be a potential strategy to prevent neurologic sequelae
in consequence of PM.
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